ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies
ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to…
February 26, 2018 - 3 minutes
Circassia
Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success
Circassia has positive Phase III results from its respiratory pipeline, great news for the company…
September 7, 2017 - 2 minutes
Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial
Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials…
April 18, 2017 - 2 minutes
Can this British Biotech Overcome Failure buying drugs from AstraZeneca?
After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to…
March 17, 2017 - 2 minutes
The 8 Biggest Biotech Medical Fails of 2016 in Europe
Although 2016 has brought plenty of good news in medical advances, biotech is an industry…
December 23, 2016 - 5 minutes
June was a Tough Month for European Biotech… #Fail
Abivax, Celyad, Circassia and Genticel - these are all European Biotechs that took a hit…
July 6, 2016 - 3 minutes
Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’
Circassia's pipeline takes a major step back as its therapy for cat allergy gets disappointing…
June 21, 2016 - 3 minutes
UK Immunotherapy against Grass Allergies moves on to Phase III Trials
Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This…
May 31, 2016 - 2 minutes
It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund
Cash is floating into Biotech like never before, in the US as well as in…
August 14, 2015 - 2 minutes
2014, the Biggest Year Ever for European Biotech IPOs
There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom…
February 6, 2015 - 3 minutes
